As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?

Name: As a leading authority in LDL-C-mediated CV risk reduction, can you provide us with your perspective on the evidence for PCSK9 inhibitors as a foundational approach for managing a broad spectrum of patients with high risk coronary heart disease?
Uploaded: 2019-03-17T00:00:00+00:00

Get Credit

Created by

Presenter

Paul Ridker, MD

Atherosclerosis Prevention
Paul Ridker, MD,
Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA